PMGC unit NorthStrive Biosciences files two US patent applications for muscle preservation in GLP-1 weight loss market

PMGC Holdings Inc.

PMGC Holdings Inc.

ELAB

0.00
  • PMGC’s wholly owned unit NorthStrive Biosciences filed two new U.S. patent applications for EL-22 and EL-32 in human muscle-preservation uses.
  • Filings target lean-mass preservation during GLP-1 obesity drug weight loss, including dual and triple agonists across GLP-1, GIP, glucagon pathways.
  • Applications assigned U.S. Patent Application Nos. 19/709,895 for EL-22, 19/709,950 for EL-32.
  • Strategy shifts IP focus from animal health into potential human pharmaceuticals, including sarcopenia, malnutrition, neurogenic atrophy, physical inactivity.
  • Claims include product formats such as peptide constructs or engineered microorganisms, with optional co-administration concepts to support muscle preservation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180730PRIMZONEFULLFEED9749071) on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.